Active MPN Research
With many clinical trials in progress, as well as clinicians and laboratory scientists around the world researching MPNs, our understanding of these diseases continues to grow. New research on the causes and treatment of MPNs is constantly being published. Here you can find links to the latest MPN research publications.
- Recent advances in the diagnosis and management of primary myelofibrosis.
- [Safety and Effectiveness of Ruxolitinib for Treatment of Myeloproliferative Neoplasm: A Meta-Analysis].
- [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].
- Can H2 -receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report.
- Molecular profile of inflammatory and megakaryocytic factors in pediatric myelodysplastic syndrome with acute myelofibrosis.
- Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations.
- Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia.
- Psychosocial impact of mast cell disorders: Pilot investigation of a rare and understudied disease.
- Increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera.
- Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
- Chorea in the older adult: a full blooded answer.
- Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.
- Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey.
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
- The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis.